Intratumor heterogeneity defines subtypes of HER2+ breast cancer with clinical implication

Date 05 March 2016
Event ESMO Symposium on Signalling Pathways in Cancer 2016
Session Targeting the EGFR/HER family in breast and gastric cancers
Topics Breast Cancer
Personalised Medicine
Translational Research
Presenter Anne-Lise Børresen-Dale
Authors A. Børresen-Dale
  • Department Of Genetics, Oslo University Hospital Rikshospitalet - Radiumhospitalet Trust, Oslo/NO